NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/12/2023
Voltar para busca
Dado oficial do USPTO
ONCOALLY
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
ONCOALLY
ST13
US500000097341559Classe
10, 42, 44
Pedido
97341559
Registro
7237702
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
32
Atualização mais recente
05/12/2023
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
10, 42, 44
Data de depósito
31/03/2022
Data de registro
05/12/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
05/12/2023
Última transação
05/12/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
31/10/2022
Primeiro uso no comércio
31/10/2022
Código do desenho
4
Tipo de titular
03
Localização do titular
Farmingham, MA, US
Examinador
CANTONE, KERI H
Unidade examinadora
L40
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Variantyx Inc.
Representantes
Mark I. Koffsky KOFFSKY SCHWALB LLC
Classificação técnica
Classes Nice
Classe 10Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 10
Medical apparatus and instrument for diagnostic useapparatus for medical diagnostic testing in the fields of cancer or other tissue-based diagnostic testingcytology and cell-based testing; Genetic testing apparatus for medical purposes; Diagnostic kits comprising of test tubescollection containers and toolsfor collecting biological samples for use in medical testing
Classe 42
Scientific laboratory services in the field of genomicsgenetic sequencinganalysis and diagnosis of biological tumor sample; Platform as a Services (PAAS) featuring computer software platforms for analyzingclassifyinginterpreting and diagnosing genetic data; Platform as a Services (PAAS) featuring computer software platforms that provide a diagnostic report based on genetic tumor profile; Platform as a Services (PAAS) featuring computer software platforms for analyzing genetic data and providing healthcare professionals information about a patient's diagnosisprognosis and treatment recommendations
Classe 44
Genetic testing for medical purposes; Consulting services in the field of genetic testing for medical purposes; Medical and health services relating to DNARNAgeneticsgenetic testing and genetic sequencing in the field of oncology; Providing medical information via the preparation of medical reportsdiagnostic reports based on genetic tumor profile; Providing medical information via medical reportsclinical reports providing disease treatment recommendations and information about disease treatment and prognosis; Providing medical information to healthcare professionals on cancer diagnosticstreatment and prognosis; Providing medical information via a website featuring information on patient genetic data for diagnosis and treatment purposes; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical laboratory services for the analysis of samples taken from patientsanalysis of biological tumor sample and genetic sequencing; Pathology services relating to the treatment of personsanalysis of biological tumor sample for medical purposes; Laboratory testing servicesgenetic testing in the field of oncology for analyzingclassifyinginterpreting and diagnosing genetic data for medical diagnostic and treatment purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
32 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
05/12/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
02/11/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
01/11/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
13/09/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
12/09/2023
EX1G
SOU EXTENSION 1 GRANTED
12/09/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
08/09/2023
IUAF
USE AMENDMENT FILED
30/08/2023
EXT1
SOU EXTENSION 1 FILED
30/08/2023
EEXT
SOU TEAS EXTENSION RECEIVED
30/08/2023
EISU
TEAS STATEMENT OF USE RECEIVED
30/08/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
18/07/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
23/05/2023
PUBO
PUBLISHED FOR OPPOSITION
23/05/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/05/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
20/04/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
19/04/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
18/04/2023
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
18/04/2023
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
10/04/2023
GNFR
FINAL REFUSAL E-MAILED
10/04/2023
CNFR
FINAL REFUSAL WRITTEN
10/04/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/03/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/03/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/03/2023
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
26/01/2023
GPRA
PRIORITY ACTION E-MAILED
26/01/2023
CPRA
PRIORITY ACTION WRITTEN
26/01/2023
DOCK
ASSIGNED TO EXAMINER
17/01/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/04/2022
NWAP
NEW APPLICATION ENTERED
04/04/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ONCOALLY ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.